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Abstract
Objectives: Development and pilot evaluation of a personalized decision support 
intervention to help men with early‐stage prostate cancer choose among active sur-
veillance, surgery, and radiation.
Methods: We developed a decision aid featuring long‐term survival and side effects 
data, based on focus group input and stakeholder endorsement. We trained premedi-
cal students to administer the intervention to newly diagnosed men with low‐risk 
prostate cancer seen at the University of California, San Francisco. Before the in-
tervention, and after the consultation with a urologist, we administered the Decision 
Quality Instrument for Prostate Cancer (DQI‐PC). We hypothesized increases in 
two knowledge items from the DQI‐PC: How many men diagnosed with early‐stage 
prostate cancer will eventually die of prostate cancer? How much would waiting 
3 months to make a treatment decision affect chances of survival? Correct answers 
were: “Most will die of something else” and “A little or not at all.”
Results: The development phase involved 6 patients, 1 family member, 2 physi-
cians, and 5 other health care providers. In our pilot test, 57 men consented, and 44 
received the decision support intervention and completed knowledge surveys at both 
timepoints. Regarding the two knowledge items of interest, before the intervention, 
35/56 (63%) answered both correctly, compared to 36/44 (82%) after the medical 
consultation (P = .04 by chi‐square test).
Conclusions: The intervention was associated with increased patient knowledge. 
Data from this pilot have guided the development of a larger scale randomized clini-
cal trial to improve decision quality in men with prostate cancer being treated in 
community settings.
K E Y W O R D S
behavioral science, cancer education, ethical considerations, prostate cancer
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1 |  BACKGROUND
Patients with low‐risk prostate cancer are vulnerable to mak-
ing decisions based on incomplete information.1 Patients have 
misconceptions about the risks and benefits of surgery, radi-
ation, and active surveillance.2-4 This can result in prostate 
cancer survivors feeling that they had more or less treatment 
than they would have chosen if they had been fully informed 
and more involved in their decisions.5-8
A systematic review with meta‐analysis of randomized 
controlled trials concluded that decision aids are associated 
with increases in patient knowledge,9 among other benefits. 
Communication aids include question‐listing interventions.10 
A systematic review with meta‐analysis found that these are 
associated with increased involvement in the form of question‐
asking.11 Members of our team have developed communication 
aiding interventions showing psycho‐social benefits for men 
with prostate cancer, including increases in decision self‐effi-
cacy (DSE) and reductions in decisional conflict and regret.12
It appears decision and communication aids can address 
deficits in patients being informed and involved. However, 
we identified two gaps in the literature.
First, decision aids in prostate cancer have not yet pro-
vided personalized estimates of risk and benefit. Two ran-
domized controlled studies of decision aids in prostate cancer 
found increased knowledge.13,14 However, these decision 
aids were not targeted specifically at low‐risk prostate cancer 
using personalized estimates of risk.15 Greater personaliza-
tion of decision aids for low‐risk patients is now possible be-
cause researchers are beginning to report long‐term outcomes 
data about mortality and side effects while stratifying results 
according to risk level.16,17
The second gap in the literature is that researchers have 
not yet studied the delivery of decision and communication 
aids by students as part of their pre‐medical training. A re-
cent review of evidence18 found three studies, in domains 
other than prostate cancer, where professional health coaches 
delivered decision aids that were associated with increased 
patient knowledge.19-21 Subsequent to the publication of this 
review, one study by Mishel et al in prostate cancer found a 
strong effect on knowledge when nurses coached patients in 
the use of decision and communication aids.14
Addressing these gaps would contribute important knowl-
edge about the impact of more specific patient education; and 
whether delivery of patient education interventions can be 
task‐shifted to students.
To address these gaps, our team developed a multi‐compo-
nent decision support intervention. First, we asked whether an 
intervention delivered by pre‐medical student interns would 
be acceptable to a focus group of stakeholders. Second, we 
asked if a personalized decision support intervention was as-
sociated with improved patient knowledge about early‐stage 
prostate cancer.
2 |  METHODS
2.1 | Approach and study design
We approached this research as formative work to assess the 
acceptability and efficacy of a novel decision support inter-
vention, while generating pilot data to estimate effect sizes 
for a future randomized controlled trial. We developed our 
intervention using qualitative methods and conducted a pre/
post test with patients at our academic medical center. We 
obtained ethics approval (14‐13332) from the Committee 
on Human Research at the University of California, San 
Francisco (UCSF). We registered the study on ClinicalTrials.
gov as number NCT02451345.
2.2 | Target population and study samples
Our target population was men with low‐risk prostate can-
cer being treated in academic and community settings in the 
United States. For the intervention design phase, we con-
vened a sample of 8 patients, 1 family member/caregiver, and 
7 healthcare professionals. For the intervention testing phase, 
we approached patients diagnosed with low‐risk disease at 
the University of California, San Francisco to discuss treat-
ment options with a urologist. The inclusion criteria included 
men age ≥18, who could speak and read English, and with 
newly diagnosed (within 6 months), low‐risk prostate cancer, 
who have not yet received therapy. Low‐risk was defined as: 
Gleason score ≤3+4, stage ≤T2N0M0, PSA ≤10 ng/mL.
2.3 | Outcomes, measures, and instruments
2.3.1 | Intervention design phase
We used a survey instrument from the International Patient 
Decision Aids Standards (IPDAS) to measure the stakeholder 
endorsement of our decision aid.22 We limited our question-
naire to 12 questions in the qualifiying and certifying criteria. 
See online supplemental materials Data S1.
We also asked stakeholders to rate the acceptability of our 
coaching intervention using the Decision Support Assessment 
Tool,23 a written survey instrument designed to evaluated the 
provision of decision coaching. See online supplemental ma-
terials Data S1.
2.3.2 | Intervention testing phase
For the intervention testing phase, we collected patient de-
mographics at baseline, and measured decision self‐efficacy 
immediately before and immediately after the intervention. 
Our intention was to orient patients to their treatment options 
and outcomes using the decision aid before the urologist con-
sultation. We also wanted to help them list questions. We 
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hypothesized that the decision aid and question listing would 
increase patient decision self‐efficacy. We measured patient 
knowledge, as described below, before the intervention and 
after the medical consultation. We wanted the patient to ask 
questions and emerge from the consultation with increased 
knowledge.
Decision quality instrument with knowledge subscale
The Decision Quality Instrument‐Early Prostate Cancer 
Treatment has a knowledge subscale with 11 questions 
which can be provided to patients in the form of a multi-
ple‐choice quiz.24 We chose five questions about survival 
outcomes and side effects that were addressed by our de-
cision aid. (See Table 1). We hypothesized that we would 
see a pre/post increase in the proportion of patients who 
answered the first two knowledge items correctly: How 
many men diagnosed with early‐stage prostate cancer will 
eventually die of prostate cancer? How much would wait-
ing 3 months to make a treatment decision affect chances 
of survival? Correct answers were: “Most will die of 
something else” and “A little or not at all.” These items 
are most relevant to patient understanding that their con-
dition is not urgently life‐threatening, and there is time to 
weigh all options thoroughly.
Decision self‐efficacy item
To assess decision self‐efficacy, we used an item from the 
decision self‐efficacy scale.25 This item was sensitive to our 
question‐listing intervention in a prior randomized controlled 
trial.12 The item requested a 0‐4 confidence rating that I can 
"Figure out the treatment choices that best suit me."
2.4 | Data collection procedures
2.4.1 | Intervention design phase
Decision scientists on our team designed an initial prototype 
of our decision aid, using the SCOPED model as a concep-
tual framework.26 SCOPED is an acronym whose letters rep-
resent steps in reflecting critically on a decision: Situation, 
Choices, Objectives, People, Evaluation, and Decisions.
To refine this prototype, we identified a representative 
group of stakeholders. We conducted rounds of feedback 
until all the stakeholders endorsed the decision aid according 
to the IPDASi standards described above.
In order to systematically incorporate stakeholder feed-
back, we used the Nominal Group Technique.27 The Nominal 
Group Technique is a focus group technique that captures 
stakeholder input in writing first, to prevent dominance of 
any especially verbal members of the group. In each round of 
feedback, we surveyed the stakeholders about the current ver-
sion of the decision aid; discussed their survey responses; and 
then voted on the acceptability of the decision aid. We contin-
ued making changes to the decision aid and getting feedback 
until all stakeholders rated the decision aid as acceptable.
Our coaching intervention to deliver the decision aid was 
based on an established approach to question listing, de-
scribed in the literature as Consultation Planning.26 To adapt 
Consultation Planning for this intervention, we recorded all 
coaching sessions, and reviewed recordings with the stake-
holder team during our biweekly calls. We asked stakehold-
ers to rate the coaching process using the Decision Support 
Analysis Tool (DSAT) survey, capturing suggestions for im-
provement and repeating until we arrived at consensus en-
dorsement of the intervention design.
2.4.2 | Intervention testing phase
Study sample
We enrolled a convenience sample of 51 patients seeing 7 urolo-
gists at UCSF, between 4/1/2015 and 2/7/17. Part‐time study co-
ordinators approached these patients based on the coordinator's 
availability and overlap with their urologist's schedule. After 
enrollment, student coaches contacted the patients to administer 
the intervention by telephone and survey instruments by email.
2.5 | Analysis plan
2.5.1 | Intervention design phase
We documented the ongoing suggestions for improve-
ment from stakeholders. All suggested modifications were 
T A B L E  1  Survey to assess patient knowledge
Five items from decision quality instrument‐early prostate 
cancer treatment24
1. Without treatment, about how many men diagnosed with 
early‐stage prostate cancer will eventually die of prostate cancer? 
Responses: Most will die of prostate cancer; About half will die of 
prostate cancer; Most will die of something else*.
2. For most men with early‐stage prostate cancer, how much would wait-
ing a few months to make a treatment decision hurt their chances of  
survival? Responses: A lot; Somewhat; A little or not at all*.
3. In the first few years after treatment for prostate cancer, which 
is more likely to cause bowel problems? Responses: Surgery; 
Radiation*; Both surgery and radiation are equally likely to cause 
bowel problems.
4. In the first few years after treatment for prostate cancer, which 
is more likely to cause sexual problems with erections? Surgery*; 
Radiation; Both surgery and radiation are equally likely to cause 
sexual problems.
5. In the first few years after treatment for prostate cancer, which 
is more likely to cause dripping or leaking urine? Responses: 
Surgery*; Radiation; Both surgery and radiation are equally likely 
to cause dripping or leaking urine.
*denotes the correct answer.
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considered by study personnel (including investigators, soft-
ware developers, and patient representatives). The study's 
co‐investigators weighed additional factors such as cost and 
technical feasibility in incorporating panelist feedback.
2.5.2 | Intervention testing phase
Decision self‐efficacy: We graphed the distribution of DSE 
scores before compared to after the intervention, and counted 
the number and proportion of patients whose DSE score rose 
vs fell. We also compared the mean DSE before and after the 
intervention using a paired t test.
Decision Quality Instrument—Knowledge: We graphed 
the distribution of knowledge scores before compared to after 
the intervention, and counted the number and proportion of 
patients whose knowledge scores rose vs fell. We compared 
the mean knowledge score before and after the intervention 
using a paired t test. We computed the proportion of patients 
who answered the first two knowledge items correctly. Then, 
we used McNemar's test for the hypothesis of no difference in 
number of patients who answered both correctly before com-
pared to after the intervention. We used Release 10 of Stata 
Statistical Software for all statistical analyses.28
3 |  RESULTS
3.1 | Intervention design phase
The stakeholder team arrived at a consensus endorsement 
of our initial decision aid after three rounds of feedback, 
and a consensus endorsement of our coaching intervention 
after one round. Based on this feedback, we concluded the 
decision aid and coaching intervention were feasible and ac-
ceptable for inclusion in the intervention testing phase of the 
study. We trained our existing premedical student interns to 
deliver the intervention.29
The training for this intervention was based on a ques-
tion‐listing curriculum we have implemented since 2012 with 
the premedical student intern workforce at UCSF. These stu-
dent interns participate in a service learning program known 
as the Patient Support Corps. Through the Patient Support 
Corps, the students earn academic credit while gaining expe-
rience working as health coaches in our medical center. Each 
year, we recruit our interns from the undergraduate student 
population at the University of California, Berkeley. We se-
lect students after a screening process that includes a writ-
ten application and interview. The application and interview 
focus on the student's competence in neutral, non‐directive 
coaching.
Through this screening process, we identify students 
who are skilled at gathering information from others; who 
can summarize and paraphrase information in a neutral fash-
ion; and who will escalate problems to supervisors when 
situations arise outside of their scope. Then the Director of 
the Patient Support Corps (first author JB), along with the 
program coordinator (author TW), train the students in their 
specific question‐listing tasks.
We administer 16  hours of classroom training in which 
the students learn a process for eliciting and documenting 
patient questions, known as the SLCT process.29 After re-
viewing videos of the process in action, trainees role‐play in 
pairs and the instructors review recordings of their role‐plays 
and provide feedback. Then the trainees are paired up with 
experienced student interns, who shadow them during pa-
tient interactions until the trainees are ready to interact with 
patients alone.
After the trainees begin interacting with patients alone, 
they submit recordings of their interactions to the program 
director and coordinator, who review recordings in group 
meetings every week, and provide ongoing training and qual-
ity improvement.
3.1.1 | Coaching and question‐listing process
We were able to leverage our existing training for coaches be-
cause the final study coaching process closely resembled our 
existing question‐listing intervention, described in the litera-
ture.26 The only material difference in this project was that, in 
addition to open‐ended question prompts, the coach also used 
the decision aid content as additional question prompts. The 
coach did this by reviewing the decision aid with the patient 
one screen at a time, checking for questions, then writing the 
questions down and asking for elaboration. Also, based on 
focus group feedback, we asked the coaches to check for pa-
tient understanding and direct the patient to additional help 
text in the decision aid when something was unclear.
3.1.2 | Decision aid content and interface
Our software team coded four versions of our decision aid as 
a result of the iterative feedback we collected. Readers may 
request a copy of the decision aid in portable document for-
mat from the corresponding author. Our software develop-
ment team deployed this decision aid as a web application 
using a JavaEE web profile and ran it on Amazon Elastic 
Beanstalk to provide automatic updates and resiliency. The 
application stored and retrieved data from a database con-
figured using the Research Electronic Data Capture platform 
(REDCap).30
3.2 | Intervention testing phase
3.2.1 | Sample description
Between April 2015 and February 2017 (4/1/15‐2/7/17), our 
clinic research coordinators enrolled a convenience sample 
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of 51 men seeing 7 urologists in our clinic. The men had a 
median age of 63 (mean 62). Racial and ethnic representation 
was 43 Caucasian/White, 2 Asian/Pacific, 6 Other/Mixed/ 
Unknown including 4 Hispanic/Latino. For employment sta-
tus, 21 reported an employment status of Working, 14 others 
Self‐employed, 11 Retired, and 5 Other/Unknown. Cancer of 
the Prostate Risk Assessment (UCSF‐CAPRA) scores ranged 
from 1‐6 (median: 2). T1c was the most common stage (63%).
3.2.2 | Decision self‐efficacy
For decision self‐efficacy (0‐4 confidence rating that I can 
"Figure out the treatment choices that best suit me"), the dis-
tribution of scores was similar before compared to after the 
intervention. The scale showed a ceiling effect, as the most 
frequent score before and after was the highest score, 4. The 
pre and post‐intervention means were not statistically signifi-
cantly different (3.43 to 3.47, P = .62).
We graphed the joint distribution of ratings, pre and post 
(see Figure 1). Figure 1 shows parallel 45‐degree lines corre-
sponding to changes in score of −2, −1, 0, and +1, while the 
responses are superimposed on the lines in bubbles whose 
size reflects the frequency of each pre/post combination. For 
example, a bubble on the +1 line shows 2 respondents rated 
their self‐efficacy at 2 before and 3 after the intervention.
Overall, Of 51 respondents to the DSE pre and post‐inter-
vention, 38 scores (72%) stayed the same (shown on the 0‐
change line), with 27 (51%) holding perfect at 4/4. Six scores 
(11%) went up one point, while six (11%) went down 1 point 
and one (2%) went down 2 points.
3.2.3 | Decision quality instrument—
knowledge
For knowledge, the distribution of total knowledge score 
after was shifted upwards compared to before. The raw im-
provement in means (2.84‐3.16) was not statistically signifi-
cant (P = .16).
We graphed the joint distribution of knowledge scores 
(see Figure 2). Figure 2 shows parallel 45 degree lines corre-
sponding to changes in score of −2, −1, 0, +1, +2, and +3, 
while the responses are superimposed on the lines in bubbles 
whose size reflects the frequency of each pre/post combina-
tion. For example, a bubble on the +1 line shows 3 respon-
dents answered 1 item correctly before and 2 items correctly 
after the intervention.
Overall, Figure 2 reveals 15 scores (29%) staying flat, 
12 (27%) going up one point, 5 (11%) going up two points, 
and one (2%) going up 3 points; while 8 (18%) went down 1 
point, and 3 (7%) went down 2 points. There were 18 (41%) 
scores that went up, and 11 (25%) that went down. This raw 
difference was not a statistically significant difference (bino-
mial sign test P = .13).
We had previously identified the first two items of the DQI 
knowledge survey as most relevant to our decision support 
intervention. Before the intervention, 35/56 (63%) got both 
these questions right. After the consultation, 36/44 (82%) got 
both these questions right (P = .04 by Chi‐Square test).
Among respondents who answered the questions at both 
timepoints, the number moving from at least one incorrect 
to both correct (7, or 16%) was higher than the number 
F I G U R E  1  Scatterplot of paired decision self‐efficacy scores 
(before and after)
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Weighted scatter plot showing pre/post decision self-efficacy






























F I G U R E  2  Scatterplot of paired total knowledge scores (before 
intervention and after consultation)
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moving from both correct to at least one incorrect (1, or 2%; 
McNemar P = .08). See Table 2.
4 |  DISCUSSION
We designed and tested a multi‐component intervention with 
personalized decision and communication aids that premedi-
cal students could deliver by telephone. Our decision aid 
broke new ground by incorporating long‐term, patient‐spe-
cific, and personalized data on both survival and side ef-
fects. We adapted a prior communication aid (Consultation 
Planning) and prompted patient questions in categories corre-
sponding to the six decision aid topics. The close integration 
of a personalized decision aid with coached question‐listing 
is also novel.
We were surprised that the intervention was not associ-
ated with pre/post changes in decision self‐efficacy. A re-
cent study of prostate cancer patients in the UK found that 
Consultation Planning alone was associated with a signifi-
cant pre/post change in DSE.12 As opposed to that study, our 
population demonstrated a ceiling effect that left little room 
for improvement. We believe that patients in community set-
tings may demonstrate lower self‐efficacy levels and benefit 
more from the intervention.
The direction and magnitude of improvement in knowl-
edge was encouraging. A subset of two key knowledge ques-
tions were especially sensitive to our intervention. We will 
use these two items as the primary outcome in a randomized 
controlled trial of our intervention vs usual care in community 
settings, with decision self‐efficacy as a secondary outcome.
4.1 | Study strengths
The strengths of our study included the participation of di-
verse stakeholders, notably patient representatives, during the 
design phase. We designed an innovative multi‐component 
intervention that was delivered by members of an untapped 
workforce—premedical students who earned academic credit 
while serving as health coaches. The intervention broke new 
ground in prostate cancer education by personalizing our de-
cision aid with risk information based on each patient's clini-
cal characteristics. In addition, we integrated the decision aid 
with our coach‐led question‐listing intervention, to assure 
that each component of our intervention flowed smoothly 
into the next.
4.2 | Study limitations
Our formative study recruited a convenience sample of pa-
tients in an academic medical center, had no control group, 
and relied on self‐reported measures collected before and 
after the intervention (self‐efficacy) and consultation with a 
urologist (knowledge). We observed knowledge gains but in 
the absence of a control group, we do not know if they would 
have occurred even without the intervention. Other limita-
tions include sampling bias (we invited patients at convenient 
times for the study coordinator), motivational bias (patients 
who consented may be different than those who did not), 
agreement bias (patients may have wanted to please study 
personnel or the clinical care team with their answers), and 
maturation bias (there could have been changes in the envi-
ronment over time relevant to our study outcomes). One of 
our measures exhibited a strong ceiling effect, which may 
not be as evident in other settings. This study was conducted 
in an academic center with urologists who are highly spe-
cialized in the care of patients with low‐risk prostate cancer, 
which may not be representative of all prostate cancer care 
settings.
4.3 | Clinical implications
The ceiling effect in decision self‐efficacy is surprising when 
juxtaposed with relatively low knowledge scores. The mode 
of the DSE distribution was the maximum score (4/4), while 
the mode of the total knowledge score was 60% (3/5). This 
suggests that patient confidence about making decisions ex-
ceeded patient knowledge. Our finding suggests that patients 
may need more education than they report, if they are to make 
decisions based on valid information. Therefore, in order to 
assure truly informed consent, clinicians should check ex-
plicitly for understanding on key facts, whether or not the pa-
tient asserts self‐efficacy for decision making. In the case of 
early‐stage prostate cancer, two key misconceptions include 
how many men diagnosed with early‐stage prostate cancer 
will eventually die of prostate cancer (most will die of some-
thing else); and how much would waiting 3 months to make 
a treatment decision affect chances of survival (a little or not 
at all). These items are most relevant to patient understanding 
that their condition is not urgently life‐threatening, and there 
is time to weigh all options thoroughly.
5 |  CONCLUSIONS
Our multi‐component decision aid intervention has po-
tential for reducing knowledge deficits about early‐stage 
T A B L E  2  Patient performance on first two knowledge items 
before and after intervention
Before Intervention
After Intervention
At least 1 incorrect Both correct
At least one incorrect 7 7
Both correct 1 29
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prostate cancer. We would like to further examine whether 
the intervention will improve knowledge and decision self‐
efficacy, in a population with lower decision self‐efficacy 
than seen in our sample. To more definitively address these 
questions we have designed and are implementing a clus-
ter‐randomized controlled trial with sites in community 
settings.
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